Targeting SLAMF in SLE with elotozumab, an anti-SLAMF7 antibody, restored NK cytotoxic cell functions in SLE patients, priming them to kill antibody-secreting plasma cells in vitro, making NK cells a target of interest in SLE management (33). This evidence concerns the gene SLAMF7 and systemic lupus erythematosus.